{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T21:57:32Z","timestamp":1763071052557},"reference-count":33,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,4,12]]},"DOI":"10.18632\/oncotarget.26831","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T21:14:51Z","timestamp":1555362891000},"page":"2709-2721","source":"Crossref","is-referenced-by-count":32,"title":["Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts"],"prefix":"10.18632","volume":"10","author":[{"given":"Jesus","family":"Delgado-Calle","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Department of Anatomy and Cell Biology, Indiana University Sc hool of Medicine, Indianapolis, IN, USA"},{"name":"Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily G.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, Indiana University Sc hool of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Maria","family":"Galmarini","sequence":"additional","affiliation":[{"name":"Research Department, PharmaMar S.A., Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Roudebush VA Medical Center, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresita","family":"Bellido","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, Indiana University Sc hool of Medicine, Indianapolis, IN, USA"},{"name":"Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Roudebush VA Medical Center, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Roodman","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"2","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Munshi","year":"2015","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Martin","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Roodman","year":"2013","journal-title":"J Bone Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/SPC.0b013e328349c524","article-title":"Bone effects of cancer therapies: pros and cons","volume":"5","author":"Roodman","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/DDDT.S94165","article-title":"Plitidepsin: design, development, and potential place in therapy","volume":"11","author":"Martin","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"35100","DOI":"10.1038\/srep35100","article-title":"Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin","volume":"6","author":"Galmarini","year":"2016","journal-title":"Sci Rep"},{"key":"8","first-page":"536","article-title":"The mechanism of action of plitidepsin","volume":"10","author":"Munoz","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"9","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/0008-5472.CAN-07-5725","article-title":"Aplidin, a marine organism-derived compound with potent antimyeloma activityand","volume":"68","author":"Chauhan","year":"2008","journal-title":"Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/sj.bjc.6604388","article-title":"Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma","volume":"98","author":"Vanderkerken","year":"2008","journal-title":"Br J Cancer"},{"key":"11","first-page":"1886","article-title":"Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"130","author":"Carella","year":"2017","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","article-title":"Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin","volume":"31","author":"Bellido","year":"2016","journal-title":"J Bone Miner Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1096\/fj.201700919RRR","article-title":"MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production","volume":"32","author":"Bellido","year":"2018","journal-title":"FASEB J"},{"key":"14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Bellido","year":"2016","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/b-catenin signaling in bone","volume":"112","author":"Bellido","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1210\/en.2014-1046","article-title":"Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes","volume":"155","author":"Bellido","year":"2014","journal-title":"Endocrinology"},{"key":"17","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1359\/jbmr.2003.18.7.1198","article-title":"Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity","volume":"18","author":"Yamamoto","year":"2003","journal-title":"J Bone Miner Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/blood.V93.9.3044","article-title":"Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2","volume":"93","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"19","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1038\/sj.onc.1203082","article-title":"RAFTK\/PYK2-dependent and -independent apoptosis in multiple myeloma cells","volume":"18","author":"Anderson","year":"1999","journal-title":"Oncogene"},{"key":"20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.onc.1201253","article-title":"Dexamethasone induces apoptosis of multiple myeloma cells in a JNK\/SAP kinase independent mechanism","volume":"15","author":"Anderson","year":"1997","journal-title":"Oncogene"},{"key":"21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12018-018-9242-3","article-title":"Glucocorticoid excess in bone and muscle","volume":"16","author":"Bellido","year":"2018","journal-title":"Clin Rev Bone Miner Metab"},{"key":"22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00223-017-0349-1","article-title":"The Proteasome and Myeloma-Associated Bone Disease","volume":"102","author":"Giuliani","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-9966-29-8","article-title":"Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types","volume":"29","author":"Li","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors","volume":"31","author":"Craviotto","year":"2016","journal-title":"J Bone Miner Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1359\/jbmr.2001.16.9.1622","article-title":"Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture","volume":"16","author":"Bonewald","year":"2001","journal-title":"J Bone Miner Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1359\/jbmr.1997.12.12.2014","article-title":"Establishment of an osteocyte-like cell line, MLO-Y4","volume":"12","author":"Bonewald","year":"1997","journal-title":"J Bone Miner Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7","article-title":"Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2","volume":"74","author":"Jilka","year":"1999","journal-title":"J Cell Biochem"},{"key":"30","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Roodman","year":"2017","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/leu.2015.229","article-title":"Blocking the ZZ domain of sequestosome1\/p62 suppresses myeloma growth and osteoclast formationand induces dramatic bone formation in myeloma-bearing bones","volume":"30","author":"Eiseman","year":"2016","journal-title":"Leukemia"},{"key":"32","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1172\/JCI82012","article-title":"Measles virus nucleocapsid protein increases osteoblast differentiation in Paget\u2019s disease","volume":"126","author":"Roodman","year":"2016","journal-title":"J Clin Invest"},{"key":"33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jbmr.3011","article-title":"Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor","volume":"32","author":"Bellido","year":"2017","journal-title":"J Bone Miner Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T10:51:02Z","timestamp":1588848662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":33,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,4,12]]}},"alternative-id":["26831","31105871"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26831","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}